Twice-Weekly Intramuscular Testosterone Cypionate/Enanthate Dosing
For twice-weekly intramuscular dosing of testosterone cypionate or enanthate, administer 50 mg IM twice weekly (total 100 mg/week), which provides more stable testosterone levels and reduces adverse effects compared to traditional biweekly dosing.
Dosing Algorithm
The FDA-approved dosing for testosterone cypionate states "50-400 mg should be administered every two to four weeks" for hypogonadal replacement 1. However, fractionating this dose into more frequent, smaller injections optimizes outcomes:
Recommended Twice-Weekly Regimen:
- 50 mg IM twice weekly (Monday/Thursday or similar spacing)
- Total weekly dose: 100 mg
- Route: Deep intramuscular injection into gluteal muscle 1
Rationale for Dose Fractionation:
More frequent dosing reduces adverse effects while maintaining efficacy. Research directly comparing 100 mg weekly versus 200 mg biweekly demonstrates that the weekly regimen significantly reduces erythrocytosis risk (1% vs 8% developing hematocrit >54%, p=0.023) while achieving equivalent testosterone levels 2. The higher peak testosterone with less frequent dosing appears responsible for increased hematocrit elevation 2.
Twice-weekly dosing further smooths the testosterone curve, minimizing the supraphysiological peaks and subtherapeutic troughs seen with biweekly administration. This approach aligns with the pharmacokinetics showing testosterone cypionate has an approximately 8-day half-life 1, making twice-weekly dosing physiologically rational.
Monitoring Requirements
Per Endocrine Society guidelines 3, 4:
Initial monitoring (3-6 months):
- Measure testosterone midway between injections (for twice-weekly, this means 3-4 days after injection)
- Target: Mid-normal range (400-700 ng/dL)
- If testosterone >700 ng/dL or <400 ng/dL, adjust dose or frequency 3
- Check hematocrit at 3-6 months
Ongoing monitoring (annually):
- Testosterone levels annually
- Hematocrit annually
- PSA and digital rectal exam (for men ≥40 years with baseline PSA >0.6 ng/mL) 4
Critical Safety Considerations
Stop therapy immediately if hematocrit >54% until it decreases to safe levels; evaluate for hypoxia/sleep apnea; reinitiate at reduced dose 3, 4. This is the most common dose-limiting adverse effect.
Obtain urology consultation if:
- PSA increase >1.4 ng/mL within 12 months 4
- Confirmed PSA >4.0 ng/mL 4
- Prostatic abnormality on digital rectal exam 4
Advantages of Twice-Weekly Over Biweekly Dosing
- Reduced erythrocytosis risk: Lower peak testosterone levels decrease hematocrit elevation 2
- Fewer mood/libido fluctuations: More stable testosterone levels minimize the "roller coaster" effect 3
- Better symptom control: Avoids the subtherapeutic trough levels that occur at 2 weeks with biweekly dosing
- Maintained efficacy: Historical data shows 100 mg weekly effectively suppresses LH/FSH and maintains normal testosterone 5
Practical Implementation
- Starting dose: 50 mg IM twice weekly for most patients
- Dose adjustments: Based on mid-interval testosterone levels at 3-6 months
- If levels too high (>700 ng/dL): Reduce to 40 mg twice weekly
- If levels too low (<400 ng/dL): Increase to 60-75 mg twice weekly
- Alternative if twice-weekly is impractical: 100 mg weekly is superior to 200 mg biweekly 2
The twice-weekly regimen requires more frequent injections but significantly improves the safety profile while maintaining full therapeutic efficacy for sexual function, energy, and other hypogonadal symptoms 2, 6.